Literature DB >> 21463783

Surgeon-performed ultrasound is superior to 99Tc-sestamibi scanning to localize parathyroid adenomas in patients with primary hyperparathyroidism: results in 516 patients over 10 years.

Brian R Untch1, Mohamed Abdelgadir Adam, Randall P Scheri, Kyla M Bennett, Darshana Dixit, Cynthia Webb, George S Leight, John A Olson.   

Abstract

BACKGROUND: Surgeon-performed cervical ultrasound (SUS) and 99Tc-sestamibi scanning (MIBI) are both useful in patients with primary hyperparathyroidism (PHPT). We sought to determine the relative contributions of SUS and MIBI to accurately predict adenoma location. STUDY
DESIGN: We performed a database review of 516 patients undergoing surgery for PHPT between 2001 and 2010. SUS was performed by 1 of 3 endocrine surgeons. MIBI used 2-hour delayed anterior planar and single-photon emission computerized tomography images. Directed parathyroidectomy was performed with extent of surgery governed by intraoperative parathyroid hormone decline of 50%.
RESULTS: SUS accurately localized adenomas in 87% of patients (342/392), and MIBI correctly identified their locations in 76%, 383/503 (p < 0.001). In patients who underwent SUS first, MIBI provided no additional information in 92% (144/156). In patients who underwent MIBI first, 82% of the time (176/214) SUS was unnecessary (p = 0.015). In 32 patients SUS was falsely negative. The reason for these included gland location in either the deep tracheoesophageal groove (n = 9) or the thyrothymic ligament below the clavicle (n = 5), concurrent thyroid goiter (n = 4), or thyroid cancer (n = 1). In 13 cases, the adenoma was located in a normal ultrasound-accessible location but was missed by the preoperative exam. In the 32 ultrasound false-negative cases, MIBI scans were positive in 21 (66%). Of the 516 patients, 7.6% had multigland disease. Persistent disease occurred in 4 patients (1%) and recurrent disease occurred in 6 (1.2%).
CONCLUSIONS: When performed by experienced surgeons, SUS is more accurate than MIBI for predicting the location of abnormal parathyroids in PHPT patients. For patients facing first-time surgery for PHPT, we now reserve MIBI for patients with unclear or negative SUS.
Copyright © 2011 American College of Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463783      PMCID: PMC5706459          DOI: 10.1016/j.jamcollsurg.2010.12.038

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  14 in total

1.  An international perspective on ultrasound training and use for thyroid and parathyroid disease.

Authors:  Barbra S Miller; Paul G Gauger; James T Broome; Richard E Burney; Gerard M Doherty
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 2.  Imaging for primary hyperparathyroidism--an evidence-based analysis.

Authors:  Radu Mihai; Dietmar Simon; Per Hellman
Journal:  Langenbecks Arch Surg       Date:  2009-07-10       Impact factor: 3.445

3.  99Tcm sestamibi--a new agent for parathyroid imaging.

Authors:  A J Coakley; A G Kettle; C P Wells; M J O'Doherty; R E Collins
Journal:  Nucl Med Commun       Date:  1989-11       Impact factor: 1.690

4.  Minimally invasive procedure for resection of a parathyroid adenoma: the role of preoperative high-resolution ultrasonography.

Authors:  Hanna Gilat; Maya Cohen; Raphael Feinmesser; Joshua Benzion; Jakob Shvero; Karl Segal; David Ulanovsky; Thomas Shpitzer
Journal:  J Clin Ultrasound       Date:  2005 Jul-Aug       Impact factor: 0.910

5.  Parathyroid localization with high-resolution ultrasound and technetium Tc 99m sestamibi.

Authors:  G P Purcell; F M Dirbas; R B Jeffrey; M J Lane; T Desser; I R McDougall; R J Weigel
Journal:  Arch Surg       Date:  1999-08

6.  Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure.

Authors:  D W Denham; J Norman
Journal:  J Am Coll Surg       Date:  1998-03       Impact factor: 6.113

7.  Surgeon-performed ultrasound: a single institution experience in parathyroid localization.

Authors:  Azad A Jabiev; John I Lew; Carmen C Solorzano
Journal:  Surgery       Date:  2009-10       Impact factor: 3.982

Review 8.  Clinical value of parathyroid scintigraphy with technetium-99m methoxyisobutylisonitrile: discrepancies in clinical data and a systematic metaanalysis of the literature.

Authors:  Martin Gotthardt; Bodo Lohmann; Thomas M Behr; Artur Bauhofer; Christiane Franzius; Meike L Schipper; Maria Wagner; Helmut Höffken; Helmut Sitter; Matthias Rothmund; Klaus Joseph; Christoph Nies
Journal:  World J Surg       Date:  2003-11-26       Impact factor: 3.352

9.  Impact of 25-hydroxyvitamin D deficiency on perioperative parathyroid hormone kinetics and results in patients with primary hyperparathyroidism.

Authors:  Brian R Untch; Michael E Barfield; Moahad Dar; Darshana Dixit; George S Leight; John A Olson
Journal:  Surgery       Date:  2007-12       Impact factor: 3.982

10.  Prospective evaluation of sestamibi scan, ultrasonography, and rapid PTH to predict the success of limited exploration for sporadic primary hyperparathyroidism.

Authors:  Allan Siperstein; Eren Berber; Richard Mackey; Mohammed Alghoul; Kristin Wagner; Mira Milas
Journal:  Surgery       Date:  2004-10       Impact factor: 3.982

View more
  11 in total

1.  Ultrasonography alone can reliably locate parathyroid tumours and facilitates minimally invasive parathyroidectomy.

Authors:  H Z Butt; M A Husainy; A Bolia; N J M London
Journal:  Ann R Coll Surg Engl       Date:  2015-08-14       Impact factor: 1.891

2.  Preoperative ¹¹C-methionine PET/CT enables focused parathyroidectomy in MIBI-SPECT negative parathyroid adenoma.

Authors:  Christina Lenschow; Peter Gassmann; Christian Wenning; Norbert Senninger; Mario Colombo-Benkmann
Journal:  World J Surg       Date:  2015-07       Impact factor: 3.352

3.  Clinical efficacy of 2-phase versus 4-phase computed tomography for localization in primary hyperparathyroidism.

Authors:  Adriana G Ramirez; Amber L Shada; Allison N Martin; Prashant Raghavan; Christopher R Durst; Sugoto Mukherjee; John R Gaughen; David A Ornan; John B Hanks; Philip W Smith
Journal:  Surgery       Date:  2016-06-11       Impact factor: 3.982

4.  Diagnosis performance of 99mTc-MIBI and multimodality imaging for hyperparathyroidism.

Authors:  Jun Zhou; Di-Yu Lu; Liang Xia; Xiao-Jie Cheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-08-08

Review 5.  Imaging techniques in parathyroid surgery for primary hyperparathyroidism.

Authors:  Arash Mohebati; Ashok R Shaha
Journal:  Am J Otolaryngol       Date:  2011-12-07       Impact factor: 1.808

6.  Effective factors on the sensitivity of preoperative sestamibi scanning for primary hyperparathyroidism.

Authors:  Nilufar Khorasani; Afshin Mohammadi
Journal:  Int J Clin Exp Med       Date:  2014-09-15

7.  Correlation between biochemical features and outcomes of preoperative imaging (SPECT-CT and Ultrasound) in primary hyperparathyroidism.

Authors:  H Anderson; K H Lim; D Simpson; S Gull; R Oprean; F Lee; C Kakos; I T Cvasciuc
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

8.  Correlation of surgeon-performed parathyroid ultrasound with the Perrier classification and gland weight.

Authors:  Matei Dordea; U Moore; J Batty; T W J Lennard; S R Aspinall
Journal:  Langenbecks Arch Surg       Date:  2018-10-20       Impact factor: 3.445

9.  The utility of thyroid ultrasonography in the management of thyroid nodules.

Authors:  Gary Gamme; Tyler Parrington; Edward Wiebe; Sunita Ghosh; Brendan Litt; David C Williams; Todd P W McMullen
Journal:  Can J Surg       Date:  2017-04       Impact factor: 2.089

10.  Value of preoperative ultrasound-guided fine-needle aspiration for localization in Tc-99m MIBI-negative primary hyperparathyroidism patients.

Authors:  Wenbo Li; Qingli Zhu; Xingjian Lai; Jian Sun; Yuxin Jiang; Xinyu Ren; Qing Zhang; Zhilan Meng; Jianchu Li; Qing Dai
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.